Neurocrine Biosciences Announces Publication Of Full Kinect-HD Phase 3 Study Results Of Valbenazine For The Treatment Of Chorea Associated With Huntington's Disease In The Lancet Neurology
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has announced the publication of full Kinect-HD Phase 3 study results of Valbenazine for the treatment of chorea associated with Huntington's disease in The Lancet Neurology.
May 19, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' publication of full Kinect-HD Phase 3 study results for Valbenazine may positively impact the company's stock price.
The publication of the full Kinect-HD Phase 3 study results in The Lancet Neurology, a prestigious medical journal, validates the effectiveness of Valbenazine for the treatment of chorea associated with Huntington's disease. This positive news may attract investors and drive up the stock price of Neurocrine Biosciences (NBIX) in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100